Energy Fuels Acquires RadTran LLC as A Further Step Toward Addressing the Global Industry Need For Medical Radioisotopes in Emerging Cancer Treatments
Energy Fuels Acquires RadTran LLC as A Further Step Toward Addressing the Global Industry Need For Medical Radioisotopes in Emerging Cancer Treatments
Acquisition intended to enhance Energy Fuels' current capabilities and support announced plans for medical isotope development.
收购旨在增强Energy Fuels的现有能力,并支持其医用同位素开发计划。
LAKEWOOD, Colo., Aug. 19, 2024 /CNW/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels"), an industry leader in uranium and rare earth elements ("REE") production for the energy transition, today announces the August 16, 2024 acquisition (the "Acquisition") of RadTran LLC ("RadTran"), a private company specializing in the separation of critical radioisotopes, to further Energy Fuels' plans for development and production of medical isotopes used in cancer treatments. RadTran's expertise includes separation of radium-226 ("Ra-226") and radium-228 ("Ra-228") from uranium and thorium process streams. This strategic acquisition is expected to significantly enhance Energy Fuels' planned capabilities to address the global shortage of these essential isotopes used in emerging targeted alpha therapies ("TAT") for cancer treatment.
科罗拉多州莱克伍德,2024年8月19日 / CNW / - uranium和氧化稀土元素("REE")的生产领域中的行业领导者Energy Fuels Inc.(NYSE American: UUUU) (TSX: EFR) ("Energy Fuels"),今天宣布了于2024年8月16日进行的收购("收购")RadTran LLC("RadTran"),后者是一家专门从事重要放射性同位素分离的私营公司,以进一步推进Energy Fuels计划中的开发和生产用于癌症治疗的医用同位素。RadTran的专业知识包括从铀和钍过程流中分离出镭-226("Ra-226")和镭-228("Ra-228")。这笔战略性收购有望显著增强Energy Fuels计划中应对这些用于新兴靶向α治疗("TAT")用于癌症治疗的必要同位素的全球短缺的能力。
![](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240820/0-de499523057bfe1f0c93b88dc64dc3cd-0-4e2de7e21f7c868d352bc750c0d57c79.jpg/big)
Mark Chalmers, President and CEO of Energy Fuels said, "With this Acquisition, we will be combining our unique processing capabilities at the White Mesa Mill, the only permitted and operating uranium mill in the United States, with over 40 years of chemical and metal separations experience, with RadTran's intellectual property and medical isotope experience in radionuclide separation and concentration, which we believe will position Energy Fuels to be a leader in this developing industry.
Energy Fuels的总裁兼首席执行官Mark Chalmers表示:"通过这次收购,我们将结合我们在美国唯一获得许可的和运营的白色平均浓度工厂的独特处理能力,配合40多年的化学和金属分离经验,以及RadTran在放射性同位素分离和浓缩方面的知识产权和医用同位素经验结合起来,我们相信这将使Energy Fuels成为这个发展中行业的领导者。"
"Additionally, what I find exciting about this initiative is that Energy Fuels has the potential to recover valuable isotopes from its existing process streams, thereby recycling back into the market material that would otherwise be lost to disposal and repurposing it for use in producing life-saving cancer treatments.
"此外,我认为这个计划令人兴奋的一点是,Energy Fuels有可能从其现有的处理过程流中获取有价值的同位素,因此将回收在市场上原本会被丢弃的材料,并重新用于生产可拯救生命的癌症治疗。"
"And our current R&D activities are being conducted using existing Mill facilities without the need for capital improvements of any significance. Capital development for future commercial production capabilities, upon successful production at the R&D level, would be expected to be supported by future offtake agreements for radium production."
"我们目前的研发活动正在使用现有的厂房设施进行,而无需进行任何重大资本改进。如果在研发阶段成功生产了商业量的Ra-226,未来在获得充足的商业化生产协议和所有必要的监管批准后,预计将于2026-2028年在白色平均浓度工厂建立商业规模的Rad-226和可能的Rad-228生产能力。"
Since July 2021, Energy Fuels and RadTran have been working under a Strategic Alliance Agreement to evaluate the feasibility of recovering Ra-226 and Ra-228 from existing uranium process streams at Energy Fuels' White Mesa Mill in Utah (the "Mill"). Recovered Ra-226 and Ra-228 would be made available to the pharmaceutical industry and others to enable the production of actinium-225 ("Ac-225"), lead-212 ("Pb-212") and potentially other leading medically attractive TAT isotopes. These isotopes are critical components in the development of targeted alpha therapies, which offer promising new treatments for various cancers. The global shortage of Ra-226 and Ra-228 currently presents itself as a significant barrier to the advancement and commercialization of these therapies.
自2021年7月以来,Energy Fuels和RadTran一直在根据战略联盟协议评估在Energy Fuels位于犹他州白色平均浓度工厂("Mill")的现有铀过程流中恢复Ra-226和Ra-228的可行性。恢复的Ra-226和Ra-228将提供给制药行业和其他地方,以启用放射性-225("Ac-225"),铅-212("Pb-212")和潜在其他先进医用TAT同位素的生产。这些同位素是用于各种癌症的有前途的新型治疗方法的关键组成部分。Ra-226和Ra-228的全球短缺目前是推动这些治疗方法的推进和商业化的一个重大障碍。
Energy Fuels received regulatory approval and licensing in 2023 for the concentration of R&D quantities of Ra-226 at the Mill and is currently completing engineering on its research and development ("R&D") pilot facility for Ra-226 production. During 2024, Energy Fuels plans to set up the first stages of the pilot facility and expects to produce R&D quantities of Ra-226 for testing by end-users of the product. Upon successful production of R&D quantities of Ra-226, Energy Fuels plans to develop capabilities at the Mill for the commercial-scale production of Ra-226 and potentially Ra-228 in 2026-2028, conditional on completion of engineering design, securing sufficient offtake agreements for final radium production, and receipt of all required regulatory approvals.
Energy Fuels于2023年获得了在实验室水平浓缩Ra-226的监管批准和许可,并正在目前建造Ra-226生产的研发样机设施。在2024年期间,Energy Fuels计划设置研发样机设施的第一阶段,并预计到产品最终用户进行测试之前,生产出研发数量的Ra-226。在成功生产研发数量的Ra-226之后,Energy Fuels计划在Mill上开发Rad-226和可能的Rad-228的商业规模生产能力,并在2026-2028年推向市场商业化,前提是完成设计工程,获得充足的产品生产商业协议和所有所需的监管批准。
Under the Acquisition, the purchase price payable by Energy Fuels to the owners of RadTran consists of (all dollar amounts in US$): (i) on closing, $1.5 million in cash, $1.5 million in Energy Fuels common shares ("Common Shares") and the grant of a 2% royalty on future revenues from the sale of produced radium, as well as certain other contractual commitments; and up to an additional $14 million in cash and Common Shares based on the satisfaction of a number of performance-based milestones, including achieving initial production, securing suitable offtake agreements to justify commercial production and reaching commercial production.
根据本次收购,Energy Fuels向RadTran的所有者支付的购买价格包括(所有美元金额):(i)在交割时,现金150万美元,能量燃料普通股150万美元和对产品产生未来收益2%的转让权,以及某些其他合同承诺,并且根据完成若干基于绩效的里程碑,包括实现初始生产,获得适当产品生产销售协议和达到商业化生产的情况下,另外支付高达1400万美元的现金和普通股。
In addition, as part of the Acquisition, Saleem Drera PhD, President and CEO of RadTran, will join Energy Fuels as Vice President of Radioisotopes, Radiological Systems, and Intellectual Property. In this role, Dr. Drera will lead Energy Fuels' efforts to integrate RadTran's proprietary technology, which includes a number of patents, pending patents, trade secrets and know-how relating to efficient separation of Ra-226 and Ra-228 from process streams, and drive innovation in the production of medical radioisotopes.
此外,作为本次收购的一部分,Saleem Drera博士,《RadTran》的总裁兼首席执行官,将加入能量燃料公司担任放射同位素、放射系统和知识产权副总裁。在这个角色中,Dr. Drera将领导Energy Fuels整合RadTran的专有技术,其中包括许多专利,待申请专利,商业机密和有关从过程流中有效分离Ra-226和Ra-228的专业知识技术,并推动医用放射同位素的生产创新。
The demand for Ra-226 and Ra-228 is underscored by the extensive clinical research currently underway. More than 30 clinical trials are evaluating Ac-225, a product of Ra-226 and a crucial component of targeted alpha therapies, highlighting the urgent need for reliable isotope supply. Notably, several of these trials have reached final pre-approval stage (phase 3) targeting neuroendocrine tumors and leukemia, with many more earlier stage trials already initiated to address common cancers including prostate cancer.
对Ra-226和Ra-228的需求得到了目前广泛的临床研究的确认。 30多项临床试验正在评估Ac-225,这是Ra-226的产物,也是靶向α疗法的关键组成部分,强调了可靠同位素供应的紧迫需求。值得注意的是,其中一些试验已经达到了最终的前批准阶段(第3阶段),针对神经内分泌瘤和白血病,并在已经启动的更多早期阶段试验中,以解决包括前列腺癌在内的常见癌症。
Critically, a shortfall in Ac-225 production (for which Ra-226 is the limiting raw material), is now delaying trials and challenging the transition to full commercial and clinical availability of these drugs. Energy Fuels intends to step in to alleviate this supply bottleneck and support development of this important new class of life-saving cancer therapies.
至关重要的是,Ac-225生产的短缺(Ra-226是限制原材料)现在正在推迟试验,也对这些药物的全面商业和临床可用性的转变带来了挑战。Energy Fuels打算介入,以缓解这一供应瓶颈,并支持这个重要的新型癌症救生药物的发展。
Saleem Drera, President and CEO of RadTran, and now Vice President Radioisotopes, Radiological Systems and Intellectual Property of Energy Fuels, said, "At RadTran, we are proud to be a part of the Energy Fuels team. The White Mesa Mill's facilities, permits and licenses, and Energy Fuels' years of experience are Ideally suited to employ RadTran's Technology. Furthermore, we have been impressed with their successful endeavors to separate and concentrate uranium, vanadium and rare earth elements in a manner that adheres to the strictest standards of protection of human health, safety and the environment."
RadTran的总裁兼首席执行官,现在是能量燃料有限公司的放射同位素、放射系统和知识产权副总裁Saleem Drera表示:"在RadTran,我们很自豪能成为能量燃料公司团队的一份子。白沙平均值工厂的设施、许可和许可证以及Energy Fuels的多年经验非常适合应用RadTran的技术。此外,我们对他们在按照保护人体健康、安全和环境最严格的标准分离和浓缩铀、钒和稀土元素方面取得的成功印象深刻。"
ABOUT ENERGY FUELS
关于Energy Fuels股份有限公司:
Energy Fuels is a leading US-based critical minerals company. The Company, as the leading producer of uranium in the United States, mines uranium and produces natural uranium concentrates that are sold to major nuclear utilities for the production of carbon-free nuclear energy. Energy Fuels recently began production of advanced rare earth element ("REE") materials, including mixed REE carbonate in 2021, and commenced production of commercial quantities of separated REEs in 2024. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the recovery of radionuclides needed for emerging cancer treatments. Its corporate offices are in Lakewood, Colorado, near Denver, and substantially all its assets and employees are in the United States. Energy Fuels holds two of America's key uranium production centers: the White Mesa Mill in Utah and the Nichols Ranch in-situ recovery ("ISR") Project in Wyoming. The White Mesa Mill is the only conventional uranium mill operating in the US today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE products, from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Company recently acquired the Bahia Project in Brazil, which is believed to have significant quantities of titanium (ilmenite and rutile), zirconium (zircon) and REE (monazite) minerals. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the US and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol "UUUU," and the Company's common shares are also listed on the Toronto Stock Exchange under the trading symbol "EFR." Energy Fuels' website is .
Energy Fuels是一家领先的基于美国的重要矿产公司。作为美国领先的铀生产商,该公司开采铀矿并生产天然铀精矿,出售给主要核电公用事业,用于生产零碳核能。Energy Fuels最近开始生产先进的稀土元素("REE")材料,包括混合REE碳酸盐("REE Carbonate"),并在2024年开始生产商业数量的分离REEs。Energy Fuels还从其一些项目中生产钒,根据市场状况确定,正在评估所需用于新兴癌症治疗的放射性同位素的恢复。其企业总部位于丹佛附近的科罗拉多州莱克伍德,其几乎所有资产和雇员都在美国境内。Energy Fuels拥有美国两个关键的铀生产中心:沃伊恩州的理查兹牧场("Nichols Ranch ISR")和尤他州的白色餐厅("White Mesa Mill")。白色餐厅是今天美国唯一正在运营的传统铀矿,拥有超过800万磅U3O8的年许可产能,能够根据市场状况生产钒和各种含铀矿石的REE产品。尼科尔斯例行化复苏项目具备年产200万磅U3O8的许可能力。该公司最近收购了位于巴西的Bahia项目,该项目被认为拥有大量的钛(钛铁矿和金红石),锆(锆石)和REE(独居石)矿物。除了以上这些生产设施,Energy Fuels还有美国最大的NI 43-101符合性铀资源组合,并拥有几个铀矿和铀/钒开采项目处于例行化和开发许可阶段。Energy Fuels普通股的主要交易市场是纽交所("NYSE American"),交易代码为"UUUU",该公司的普通股还在多伦多证券交易所("Toronto Stock Exchange")上市,交易代码为"EFR"。Energy Fuels的网站是。
Cautionary Note Regarding Forward-Looking Statements: This news release contains certain "Forward Looking Information" and "Forward Looking Statements" within the meaning of applicable United States and Canadian securities legislation, which may include, but are not limited to, statements with respect to: any expectation that the Company will maintain its position as a leading U.S.-based critical minerals company or as the leading producer of uranium in the U.S.; any expectation that the Company will complete engineering on its R&D pilot facility for the production of Ra-226 at the Mill, will set up the first stage of the pilot facility, and produce R&D quantities of Ra-226 at the Mill for testing by end-users of the product or at all; any expectation that the Company's evaluation of radioisotope recovery at the Mill will be successful; any expectation that the potential recovery of medical isotopes from any radioisotopes recovered at the Mill will be feasible; any expectation that any radioisotopes that can be recovered at the Mill will be sold on a commercial basis; any expectation that the Acquisition will significantly enhance Energy Fuels' capabilities to address the global shortage of the essential isotopes used in emerging TAT cancer treatments; any expectation that RadTran's technology will enable the efficient separation of Ra-226 and Ra-228 from process streams, or will transform them into valuable sources for medical use; any expectation that the development of TAT therapies will be successful or will offer promising new treatments for various cancers; any expectation that Energy Fuels will be or become at the forefront of the medical radioisotope supply chain; any expectation that any additional licensing for the R&D or commercial production of Ra-226, Ra-228 or any other radioisotopes at the Mill will be obtained on a timely basis or at all; any expectation as to the supply of or demand for Ra-226 and/or Ra-228 or any other isotopes; any expectation as to the successful approval or the timing of approval of any medical isotopes or TAT therapeutics; any expectation that Energy Fuels will step in to alleviate any supply bottlenecks or support development of TAT therapies; any expectation that Energy Fuels will be a leader in the supply of radioisotopes for TAT therapeutics; any expectation as to capital requirements for Energy Fuels' R&D and potential commercial radium production facilities; any expectation that future capital requirements will be supported by offtake agreements for radium production; and any expectation that Energy Fuels' operations will be or continue to be performed in a manner that adheres to the strictest standards for protection of human health, safety and the environment. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans," "expects," "does not expect," "is expected," "is likely," "budgets," "scheduled," "estimates," "forecasts," "intends," "anticipates," "does not anticipate," or "believes," or variations of such words and phrases, or state that certain actions, events or results "may," "could," "would," "might" or "will be taken," "occur," "be achieved" or "have the potential to." All statements, other than statements of historical fact, herein are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements express or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices and price fluctuations; engineering, construction, processing and mining difficulties, upsets and delays; permitting and licensing requirements and delays; changes to regulatory requirements; legal challenges; the availability of feed sources for the Mill; competition from other producers; public opinion; government and political actions; market factors, including future demand for radium; the ability of the Mill to recover radium or other radioisotopes at reasonable costs or at all; market prices and demand for medical isotopes; and the other factors described under the caption "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar, on SEDAR+ at , and on the Company's website at . Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law.
关于前瞻性声明的警告:本新闻稿包含某些适用于美国和加拿大证券法规的"前瞻性信息"和"前瞻性声明",这些信息和声明可能包括但不限于关于以下方面的声明:任何预期该公司将保持其作为领先美国的关键矿产公司或美国铀领先生产商的地位;任何预期该公司将完成其用于在磨坊上生产Ra-226的R&D试验设施的工程,并将建立试验设施的第一阶段,并在磨坊上生产研发数量的Ra-226以供产品最终用户测试或所有;任何预期该公司在磨坊上对放射性同位素的恢复评估将取得成功;任何预期从在磨坊上恢复的任何放射性同位素中回收医疗同位素的潜在回收将是可行的;任何预期在磨坊能够恢复的任何放射性同位素将以商业方式销售;任何预期收购将极大地增强Energy Fuels解决新兴TAt癌症治疗中所使用的关键同位素全球短缺的能力;任何预期RadTran技术将使Ra-226和Ra-228从工艺流中高效分离或将其转变为用于医疗用途的有价值的来源;任何预期TAt治疗的开发将成功或将为各种癌症提供有前途的新治疗方法;任何预期Energy Fuels将成为医用放射同位素供应链的先锋;任何预期在磨坊上进行R&D或商业生产Ra-226、Ra-228或任何其他放射性同位素的任何其他许可证将及时获得或获得;对Ra-226和/或Ra-228或任何其他同位素的供应和需求的任何预期;任何预期任何医用同位素或TAt治疗的批准或批准时间;任何预期Energy Fuels将解除任何供应瓶颈或支持TAt治疗的开发;任何预期Energy Fuels将成为TAt治疗用放射性同位素的供应领导者;任何R&D和潜在商业镭生产设施的资本需求;未来资本需求将由镭生产的销售合同支持;以及预计Energy Fuels的运营将或继续以严格保护人类健康、安全和环境的标准进行。一般而言,这些前瞻性陈述可以通过使用前瞻性术语,如“计划”,“预计”,“不预计”,“预期”,“可能”,“预算”,“已安排”,“估计”,“预测”,“意图”,“预计”,“不预计”或“相信”,或变化的这些词或短语,或声明某些行动、事件或结果是“可能的”,“可能的”,“将被采取”,“出现”,“被实现”或“具有潜力”等,来识别。此处除历史事实陈述外,所有言论均视为前瞻性陈述。前瞻性陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致该公司的实际结果、绩效或成就与任何未来结果、绩效或成就有实质性不同,无论是明示或暗示的前瞻性陈述。可能导致实际结果与此类前瞻性陈述所预期的结果不同的因素包括与商品价格和价格波动、工程、建设、加工、开采难题、翻覆和延误、许可证和许可证法规要求和延误、法律挑战、磨坊用料来源的可用性、其他生产者的竞争、公众舆论、政府和政治行动、市场因素(包括镭的未来需求)、磨坊能够以合理成本或根本恢复镭或其他放射性同位素、医用同位素的市场价格和需求;以及在该公司最近提交的最新年度报告表格10-k中描述的其他因素的影响,该报告可在EDGAR 上查看,网址为www.sec.gov/ edgar,在Sedar+上查看,网址为 ,以及在该公司的网站上,地址为 。此处所包含的前瞻性陈述是自本新闻发布之日起发表的,该公司除法律要求外,不承担任何更新任何前瞻性陈述的责任,无论是因为获得新信息、结果、未来事件、情况,还是管理估计或意见发生变化,或其他原因。无法保证前瞻性陈述将证明是准确的,因为实际结果和未来事件可能与这些声明所预期的不同。因此,读者应谨慎对待前瞻性陈述。该公司假设本通信中的信息除法律要求外不经更新。
SOURCE Energy Fuels Inc.
消息来源Energy Fuels Inc。